Systemic lupus erythematosus and atherosclerosis: Review of the literature

Autoimmunity Reviews

Volumn 15, Issue 1, 2016, Pages 16-21

  Frieri, Marianne ^a   Stampfl, Heather ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adaptive immunity; Complement; Cytokines; Innate; Interferon

Indexed keywords

ANTIOXIDANT; BELIMUMAB; CD40 LIGAND; CYTOKINE; INFLAMMASOME; INTERFERON; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; LIGAND;

ADAPTIVE IMMUNITY; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ACTIVATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; EXTRACELLULAR TRAP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LEUKOCYTE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MONOCYTE; NEUTROPHIL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY; RISK FACTOR;

ATHEROSCLEROSIS; CYTOKINES; HUMANS; IMMUNITY, INNATE; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 84955215319     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.08.007     Document Type: Review

References (34)

1. Pinegin B., Vorobjeva N., Pinegin V. Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity. Autoimmun Rev 2015, 14(7):633-642.
2. Smith C.K., Kaplan M.J. The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2015, 27(5):448-453.
3. Wigren M., Nilsson J., Kaplan M.J. Pathogenic immunity in systemic lupus erythematous and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med 2015, 26.
4. Frieri M. Complement related diseases. Allergy Asthma Proc 2002, 23:319-324.
5. Frieri M. Identification of masqueraders of autoimmune disease in the office. Allergy Asthma Proc 2003, 24(6):421-429.
6. Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol 2013, 110:228-232.
7. Turano L. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus: understanding management strategies. J Cardiovasc Nurs 2013, 28(1):48-53.
8. Kiani A.N., Magder L.S., Post W.S., Szklo M., Bathon J.M., Schreiner P.J., et al. Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. Rheumatology 2015, 22. [Oxford].
9. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21(12):1876-1890.
10. Denas G., Jose S.P., Bracco A., Zoppellaro G., Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015, 14(3):214-222.
11. Hollan I., Meroni P.L., Ahearn J.M., Cohen Tervaert J.W., Curran S., Goodyear C.S., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013, 12(10):1004-1015.
12. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 96(86):515-581.
13. de Souza A.W., Westra J., Limburg P.C., Bijl M., Kallenberg C.G. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012, 11(12):909-917.
14. Shirali A.C., Goldstein D.R. Tracking the toll of kidney disease. J Am Soc Nephrol 2008, 19(8):1444-1450.
15. Frieri M. TLR and VEGF in human kidneys from lupus nephritis patients. J Nephrol 2012, 25(6):1041-1046.
16. Zubair A., Frieri M. Lupus nephritis: review of the literature. Curr Allergy Asthma Rep 2013, 13(6):580-586.
17. Sprague A.H., Khalil R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009, 78(6):539-552.
18. Mikołajczyk T.P., Osmenda G., Batko B., Wilk G., Krezelok M., Skiba D., et al. Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus 2015, 6.
19. Korman B.D., Huang C.C., Skamra C., Wu P., Koessler R., Yao D., et al. Inflammatory expression profiles in monocyte-to-macrophage differentiation in patients with systemic lupus erythematosus and relationship with atherosclerosis. Arthritis Res Ther 2014, 16(4):R147.
20. Kisiel B., Kruszewski R., Juszkiewicz A., Raczkiewicz A., Bachta A., Kłos K., et al. Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques--a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima media thickness. Acta Cardiol 2015, 70(2):169-175.
21. Schönbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001, 89(12):1092-1103.
22. Li Z., Ju Z., Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc 2013, 34(1):e21-e26.
23. Borba E.F., Bonfa E. Long term beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001, 28:780-785.
24. Benvenuti F., Gatto M., Larosa M., Iaccarino L., Punzi L., Doria A. Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. Expert Opin Drug Saf 2015, 27:1-13.
25. Yildirim-Toruner C., Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011, 127:303-312.
26. Madeo J., Zubair A., Frieri M. A review on the role of quinones in renal disorders. Springer plus 2013, 2(1):139.
27. Zubair A., Frieri M. NF-kB and systemic lupus erythematosus: examining the link. J Nephrol 2013, 26:953-959.
28. Frieri M., Heuser W., Bliss J. Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis. J Pharmacol Pharmacother 2015, 6(2):71-76.
29. Xiong W., Lahita R.G. Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2011, 3(5):255-266.
30. Knight J.S., Kaplan M.J. Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013, 1000.
31. Sran S., Ferguson N., Sran M., Anand P., Makaryus A.N., Frieri M. The role of interferon in premature atherosclerosis in systemic lupus erythematosus patients. J Autoimmune Dis Rheumatol 2014, 2(2):66-70.
32. Mohan S., Barsalou J., Bradley T.J., Slorach C., Reynolds J.A., Hasni S., et al. Brief report: endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2015, 67(8):2257-2262.
33. Clement M., Charles N., Escoubet B., Guedj K., Chauveheid MP Caligiuri G., et al. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. J Autoimmun 2015, 13.
34. Kahlenberg J.M., Thacker S.G., Berthier C.C. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 2011, 187(11):6143-6156.